



Review

The PPAR β/δ -AMPK Connection in the Treatment of Insulin Resistance

David Aguilar-Recarte ^{1,2,3} , Xavier Palomer ^{1,2,3}, Walter Wahli ^{4,5,6} and Manuel Vázquez-Carrera ^{1,2,3,*}

- ¹ Department of Pharmacology, Toxicology and Therapeutic Chemistry, Institute of Biomedicine of the University of Barcelona (IBUB), Faculty of Pharmacy and Food Sciences, University of Barcelona, Avinguda Joan XXIII 27-31, 08028 Barcelona, Spain; d.aguilarrcarte@gmail.com (D.A.-R.); xpalomer@ub.edu (X.P.)
- ² Pediatric Research Institute-Hospital Sant Joan de Déu, 08950 Esplugues de Llobregat, Spain
- ³ Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos III, 28029 Madrid, Spain
- ⁴ Center for Integrative Genomics, University of Lausanne, CH-1015 Lausanne, Switzerland; walter.wahli@unil.ch
- ⁵ Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore 308232, Singapore
- ⁶ ToxAlim (Research Center in Food Toxicology), INRAE, UMR1331, CEDEX, 31300 Toulouse, France
- * Correspondence: mvazquezcarrera@ub.edu

Abstract: The current treatment options for type 2 diabetes mellitus do not adequately control the disease in many patients. Consequently, there is a need for new drugs to prevent and treat type 2 diabetes mellitus. Among the new potential pharmacological strategies, activators of peroxisome proliferator-activated receptor (PPAR) β/δ show promise. Remarkably, most of the antidiabetic effects of PPAR β/δ agonists involve AMP-activated protein kinase (AMPK) activation. This review summarizes the recent mechanistic insights into the antidiabetic effects of the PPAR β/δ -AMPK pathway, including the upregulation of glucose uptake, muscle remodeling, enhanced fatty acid oxidation, and autophagy, as well as the inhibition of endoplasmic reticulum stress and inflammation. A better understanding of the mechanisms underlying the effects resulting from the PPAR β/δ -AMPK pathway may provide the basis for the development of new therapies in the prevention and treatment of insulin resistance and type 2 diabetes mellitus.

Keywords: PPAR β/δ ; AMPK; GDF15; insulin resistance; type 2 diabetes mellitus



Citation: Aguilar-Recarte, D.; Palomer, X.; Wahli, W.; Vázquez-Carrera, M. The PPAR β/δ -AMPK Connection in the Treatment of Insulin Resistance. *Int. J. Mol. Sci.* **2021**, *22*, 8555. <https://doi.org/10.3390/ijms22168555>

Academic Editor: Wolfgang Graier

Received: 22 July 2021
Accepted: 5 August 2021
Published: 9 August 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Insulin Resistance: A Major Determinant of Type 2 Diabetes Mellitus

The prevalence of type 2 diabetes mellitus has reached global epidemic proportions and is one of the medical challenges of the 21st century [1]. Type 2 diabetes mellitus is defined by the presence of fasting hyperglycemia, which is responsible for the development of long-term complications, a decreased quality of life, and premature death [1]. It should be noted that abnormal glucose regulation may begin more than 10 years before the diagnosis of type 2 diabetes mellitus with the development of obesity-associated insulin resistance, which is defined as an impairment in the ability of insulin to maintain glucose homeostasis. However, at this early stage, subjects are asymptomatic, with glycemic values near normal levels because pancreatic islets usually respond by increasing insulin secretion to maintain normoglycemia in a process known as β cell compensation. Over time, β cell compensation for insulin resistance fails, resulting in fasting hyperglycemia and the establishment of type 2 diabetes mellitus [2]. As insulin resistance precedes and predicts type 2 diabetes mellitus [3], the development of new effective pharmacological approaches that prevent or delay its progression to type 2 diabetes mellitus relies on targeting the underlying pathological mechanisms. This is of paramount importance as current treatment options do not adequately control hyperglycemia or prevent the negative impact of type 2 diabetes

mellitus in all patients. Among the new pharmacological strategies for treating obesity-induced insulin resistance and type 2 diabetes mellitus, Peroxisome Proliferator-Activated Receptor (PPAR) β/δ agonists show promise [4–6]. Ligands of this nuclear receptor have been reported to ameliorate insulin resistance and type 2 diabetes mellitus mainly through the activation of AMP-activated protein kinase (AMPK), a central regulator of multiple metabolic pathways. This review summarizes the recent mechanistic insights into how PPAR β/δ activates AMPK to ameliorate insulin resistance and type 2 diabetes mellitus.

2. Basic PPAR β/δ and AMPK Features

PPARs are members of the nuclear receptor superfamily of ligand-inducible transcription factors. The PPAR subfamily comprises three isotypes: PPAR α (NR1C1: nuclear receptor subfamily 1, group C, member 1, according to the nomenclature agreed by the NC-IUPHAR Subcommittee on Nuclear Hormone Receptors), PPAR β/δ (NR1C2), and PPAR γ (NR1C3) [4–6]. The PPAR β/δ isotype is ubiquitously expressed, but is most abundant in metabolically active tissues/cells, mainly those associated with fatty acid (FA) metabolism such as skeletal and cardiac muscle, hepatocytes, and adipocytes, and in macrophages. Ligand binding and activation of PPAR β/δ lead to its heterodimerization with its obligate dimerization partner retinoic acid receptor (RXR or NR2B). These heterodimers then bind to peroxisome proliferator response elements (PPREs) located in the promoters of their target genes to regulate their transcription. PPAR β/δ also regulates gene expression through DNA-independent mechanisms via crosstalk with other transcription factors [4–6]. Furthermore, it has been proposed that PKC α is a binding partner of PPAR β/δ , suggesting it as a mechanism through which the receptor may impact platelet reactivity [7]. Another example for a non-genomic effect of PPAR β/δ is the ligand-dependent interaction of the receptor with T-cell protein tyrosine phosphatase 45 (TCPTP45), which enhances insulin signaling [8]. In addition, the physiological activation status of PPAR β/δ depends on the presence of tissue-enriched specific ligands and the recruitment of coactivators or corepressors. Many of the target genes regulated by PPAR β/δ are involved in lipid and glucose metabolism, tissue repair, and inflammation [4–6]. The natural ligands of all PPAR isotypes are polyunsaturated and saturated FAs and their derivatives, but most of them show little receptor isotype selectivity. The development of several synthetic ligands with a high affinity and specificity for PPAR β/δ (GW501516, GW0742, and L-165041) has helped the understanding of the functions and pharmacology of this nuclear receptor [6] (Figure 1). Although no selective PPAR β/δ agonists have yet been approved for human use, several ongoing clinical trials are studying the efficacy and safety of several compounds selectively targeting this nuclear receptor: ASP0367 and ASP1128 (Mitobridge/Astellas Pharma, Cambridge, USA), MBX-8025 or Seladelpar (CymaBay Therapeutics, Newark, NJ, USA), and REN-001 (Reneo Pharmaceuticals, San Diego, CA, USA).

Over the last twenty years, many studies have robustly demonstrated that PPAR β/δ is crucial in regulating lipid metabolism and glucose homeostasis. Consequently, its activation is especially helpful in experimental models to prevent insulin resistance, type 2 diabetes mellitus, and associated metabolic disorders. Interestingly, many of the antidiabetic effects of the PPAR β/δ activators involve the activation of AMPK [6].

AMPK is a protein kinase that protects against insulin resistance and is activated by a low cellular energy status and glucose starvation [9]. These conditions, which activate AMPK, are signaled by the rise of the cellular AMP/ATP and ADP/ATP ratios. Once activated, AMPK triggers catabolic pathways that generate ATP and inhibits anabolic pathways that consume ATP. The heterotrimeric structure of AMPK comprises the α catalytic subunit and the regulatory β and γ subunits [9–11]. The binding of AMP to the γ subunit promotes AMPK activation through the phosphorylation of a conserved threonine (Thr172) residue within the α subunit via three complementary mechanisms: (1) phosphorylation by the upstream kinases liver kinase B1 (LKB1), Ca²⁺/calmodulin-dependent protein kinase kinase β (CaMKK β), and transforming growth factor β -activated kinase 1 (TAK1); (2) inhibition of Thr172 dephosphorylation by protein phosphatases;

and (3) allosteric activation. In addition to AMP, ADP also activates AMPK through mechanisms 1 and 2, while ATP inhibits these three mechanisms [9–11].




Figure 1. PPARβ/δ agonists and AMPK activators and current status in clinical pipeline. AICAR, 5-aminoimidazole-4-carboxamide ribonucleoside.

Given the importance of AMPK in lowering insulin resistance and associated metabolic disorders, many AMPK activators with different mechanisms of action have been developed. The most important AMPK activator is metformin, which is the most prescribed drug for type 2 diabetes mellitus treatment (Figure 1). However, its mechanism of action remains to be fully elucidated [12]. It has been reported that pharmacological metformin concentrations directly activate AMPK. By contrast, suprapharmacological metformin concentrations inhibit mitochondrial complex I, thereby reducing mitochondrial ATP production and increasing cellular AMP levels that subsequently activate AMPK [10,12]. A novel direct AMPK activator, PXL770 (Poxel), is being evaluated in an ongoing clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov) 3 August 2021). In addition, many natural products, including resveratrol [13] and berberine [14], also indirectly activate AMPK by increasing cellular AMP levels. Another group of AMPK activators are AMP analogs, such as 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), which activate the γ subunit of AMPK [15]. A different group of ligands, exemplified by A-769662, includes synthetic direct activators that promote the allosteric activation of AMPK and the protection against Thr172 dephosphorylation [16,17]. Tetrahydrofolate analogs such as pemetrexed and methotrexate constitute another group of AMPK activators. These molecules inhibit the metabolism of ZMP, the phosphorylated form of AICAR, and promote its accumulation and subsequent activation of AMPK [18,19]. Finally, AMPK inhibitors are also useful in elucidating the effects mediated by this kinase. Compound C/dorsomorphin is an ATP-competitive AMPK inhibitor. However, this inhibitor is not specific for AMPK and shows AMPK-independent cellular effects [20]. More recently, a new direct inhibitor of AMPK has been characterized, SBI-0206965, with a 40-fold greater potency than compound C [21].

Once AMPK is activated, it phosphorylates key metabolic substrates and transcriptional regulators that affect many aspects of cellular metabolism, increasing glucose uptake, FA oxidation, mitochondrial oxidative capacity, and insulin sensitivity [22,23]. Interestingly, a high-fat diet (HFD) reduces AMPK phosphorylation levels in the skeletal muscle, liver, and other tissues, thereby indicating that restoration of the activity of this kinase can overcome metabolic alterations associated with the overconsumption of fat in animal models.

3. PPAR β/δ as a Major Regulator of Insulin Resistance through AMPK Activation

In the following sections of the review, we discuss studies that implicate AMPK activation in the antidiabetic effects of PPAR β/δ ligands in the main organs involved in insulin resistance.

3.1. Skeletal Muscle

The primary site of insulin resistance in obesity and type 2 diabetes mellitus is the skeletal muscle, as it accounts for around 80% of insulin-stimulated glucose disposal [24–26]. Activation of AMPK in skeletal muscle by contraction (a process that results in a significant decrease in cellular ATP levels) or by activators of this kinase is associated with an insulin-independent mechanism that stimulates glucose transporter 4 (GLUT4) vesicle trafficking to the plasma membrane, resulting in elevated glucose transport into muscle, which lowers plasma glucose levels. This mechanism involves the phosphorylation by AMPK of tre-2/USP6, BUB2, cdc16 domain family member 1 (TBC1D1) and TBC1D4 (also known as Akt substrate of 160 kDa, AS160) [27], and phosphatidylinositol 3-phosphate 5-kinase [28]. Contrary to what was initially believed, a recent study suggested a role for AMPK in the regulation of insulin-stimulated glucose uptake [29]. The PPAR β/δ agonist GW501516 was reported to upregulate basal and insulin-stimulated glucose uptake in cultured primary human skeletal myotubes through AMPK activation [30], providing a role for AMPK in the antidiabetic effects of PPAR β/δ agonists (Figure 2). The authors of the study later reported that the activation of AMPK by GW501516 could be due to a reduction of the cellular energy status, as they observed an increase in the AMP/ATP ratio [31] (Figure 3). Moreover, transgenic mice with muscle-specific overexpression of PPAR β/δ show increased levels of mitochondrial enzymes and oxidative muscle fibers, which are more resistant to fatigue than glycolytic fibers, resulting in enhanced running endurance [32]. Notably, this overexpression of PPAR β/δ is accompanied by AMPK activation, with GW501516 and exercise training synergistically increasing oxidative myofibers and running endurance [33] (Figure 2). In the skeletal muscle of these mice, there is an interaction between PPAR β/δ and AMPK that is accompanied by more glycogen stores, increased levels of GLUT4, and an augmented capacity for mitochondrial pyruvate oxidation [34]. Thus, PPAR β/δ mimics the effects of endurance exercise training and GW501516 could be used as an exercise mimetic. In fact, this compound, sold under the name of Cardarine, has been misused for performance enhancement [35] and was entered into the list of prohibited substances in 2009 by the World Anti-Doping Agency [36]. This effect of PPAR β/δ was initially reported not to be associated with an increase in the mRNA levels of PPAR γ co-activator 1 α (PGC-1 α) [32]. PGC-1 α mediates mitochondrial biogenesis and its upregulation is associated with adaptation to endurance exercise through increased muscle mitochondrial numbers. However, later studies confirmed that PPAR β/δ does increase the protein levels of this transcriptional co-activator [37,38]. More recently, an elegant study revealed the mechanisms by which PPAR β/δ increased PGC-1 α levels and activated AMPK in skeletal muscle during exercise [39]. PPAR β/δ increased PGC-1 α protein levels via a post-transcriptional mechanism by protecting it from degradation through binding to PGC-1 α and limiting its ubiquitination. PPAR β/δ also promoted the transcription of nuclear respiratory factor 1 (NRF-1), resulting in increases in the mitochondrial respiratory chain and in the transcription of CaMKK β , ultimately leading to AMPK activation [38] (Figure 3). Overall, these findings showed that PPAR β/δ is essential for the maintenance and increase in mitochondrial enzymes, unveiling a new mechanism through which this nuclear receptor activates AMPK. This conclusion is supported by the phenotype of mice in which PPAR β/δ is selectively ablated in skeletal muscle myocytes. This somatic mutation causes a muscle fiber-type switching toward lower oxidative capacity that results in markedly reduced capacity to sustain running exercise, obesity, and type 2 diabetes mellitus [37].




Figure 2. Antidiabetic effects of the PPARβ/δ-AMPK pathway in different organs. AMPK, AMP-activated protein kinase; ER, endoplasmic reticulum; GDF15, growth differentiation factor 15; PPARβ/δ: peroxisome proliferator-activated receptor β/δ; SOCS3: suppressor of cytokine signaling 3; STAT3: signal transducer and activator of transcription 3.




Figure 3. Mechanisms involved in the activation of AMPK by PPARβ/δ. AMPK is activated by PPARβ/δ through three mechanisms: (1) an increased AMP/ATP ratio; (2) an increased transcription of CaMKKβ; and (3) increased levels of GDF15 that sustain AMPK activation. AMPK, AMP-activated protein kinase; CaMKKβ, Ca²⁺/calmodulin-dependent protein kinase kinase-β; GDF15, growth differentiation factor 15; PPARβ/δ: peroxisome proliferator-activated receptor β/δ.

In obesity, as the amount of visceral adipose tissue increases, so does the rate of lipolysis. This increases FA mobilization and raises the levels of circulating non-esterified FAs, which induce insulin resistance in skeletal muscle through activation of toll-like receptor (TLR)-dependent mechanisms or by promoting the accumulation of deleterious

complex FA derivatives such as diacylglycerol (DAG) and ceramides. These pathways ultimately activate kinases (I κ B kinase β , c-Jun N-terminal kinase 1, and protein kinase C θ) that phosphorylate insulin receptor substrate 1 (IRS-1) on serine residues, attenuating the insulin signaling pathway [40]. The activation of PPAR β/δ in myotubes has been reported to transcriptionally upregulate the expression of target genes involved in FA β -oxidation such as pyruvate dehydrogenase kinase 4 (PDK4) and carnitine palmitoyltransferase-1 β (CPT-1 β). The increase in the expression of these genes promotes FA β -oxidation and reduces their availability to form complex lipids that induce insulin resistance [41] (Figure 2). CPT-1 β , which catalyzes the rate-limiting step of mitochondrial FA oxidation, is inhibited by malonyl-CoA, a product of acetyl-CoA carboxylase (ACC) [22]. AMPK phosphorylates and inhibits ACC, thereby causing a decrease in intracellular malonyl-CoA levels, relieving CPT-1 β inhibition and increasing FA oxidation. Therefore, PPAR β/δ activation in skeletal muscle increases mitochondrial FA oxidation by upregulating the expression of the target genes involved in this process as well as through increasing CPT-1 β activity by phosphorylating AMPK.

In obese patients, the release of free FAs from visceral adipose tissue is also an important factor that triggers endoplasmic reticulum (ER) stress. This process induces insulin resistance by several mechanisms including the activation of inflammatory pathways, which activate the serine/threonine kinases that phosphorylate IRS-1 on serine residues [42]. PPAR β/δ ligands inhibit ER stress in skeletal muscle through a mechanism that seems to involve AMPK activation and the subsequent inhibition of extracellular signal-regulated kinase (ERK1/2) (Figure 2). In fact, AMPK activation protects against several deleterious processes by reducing ER stress [43–46]. Notably, there is inhibitory crosstalk between AMPK and ERK1/2 [47], with the inhibition of ERK1/2 promoting AMPK and Akt signaling and reversing ER stress-induced insulin resistance in skeletal muscle cells [48]. Therefore, PPAR β/δ ligands seem to require the activation of AMPK to inhibit ER stress, which strongly contributes to the antidiabetic effects of these compounds.

Recently, we reported that the metabolic effects caused by the pharmacological activation of PPAR β/δ may involve the stress-activated cytokine growth differentiation factor 15 (GDF15) [49]. This divergent member of the transforming growth factor β (TGF β) superfamily [50] plays an important role in several biological processes, including the regulation of energy homeostasis [51]. In fact, overexpression of *Gdf15* in mice ameliorates glucose tolerance and insulin sensitivity and lowers body weight, although no difference in food intake was observed [52]. By contrast, administration of GDF15 to rodents reduces food intake and ameliorates glucose tolerance. Interestingly, a recent study reports that high pharmacological doses of GDF15 used in most studies reduce food intake, while physiological induction of endogenous circulating GDF15 levels does not affect it [53]. Although TGF β receptors were initially reported to mediate the effects of GDF15, the presence of TGF β contamination in recombinant GDF15 and the lack of a direct binding of GDF15 to known TGF β receptors led to the search for the bona fide receptor of GDF15. Four independent groups reported in 2017 that GDF15 signals through the glial cell line-derived neurotrophic factor (GDNF)-like alpha-1 (glial cell-derived neurotrophic factor receptor alpha-like (GFRAL))/rearranged during transfection (RET) co-receptor complex [54–57]. The expression of GFRAL is limited to the central nervous system, specifically in the area postrema of the brainstem and parts of the nucleus of the solitary tract. Its activation by GDF15 in obesity improves glucose tolerance by reducing food intake. However, it has been reported that GDF15 also regulates metabolic parameters independently of changes in food intake [58], suggesting that GDF15 might also exert its effects via other receptors and peripheral mechanisms. We have reported recently that PPAR β/δ ligands increase GDF15 levels through an AMPK-p53-dependent mechanism [49]. Interestingly, the beneficial effects of the PPAR β/δ agonist GW501516 on glucose intolerance, FA oxidation, ER stress, inflammation, and AMPK activation in HFD-fed mice were abrogated by the injection of a GDF15-neutralizing antibody as well as in *Gdf15*^{-/-} mice. More importantly, these findings demonstrated that the increase in GDF15 caused by PPAR β/δ activation resulted in AMPK

activation that did not require central effects, as these effects were observed in cultured myotubes and isolated muscle, suggesting the presence of autocrine/paracrine effects for GDF15 in skeletal muscle for which the mediating receptor remains to be identified (Figure 3). Although additional studies are needed to reject the potential involvement of GFRAL on the GDF15-mediated antidiabetic effects of PPAR β/δ agonists, as *Gfral* mRNA is absent in C2C12 cells [49,55] and skeletal muscle [49,59], the GDF15-mediated activation of AMPK in isolated skeletal muscle and cultured myotubes seems to exclude this receptor. The question that remains unanswered is the identity of the new potential receptor responsible for the autocrine/paracrine effects of GDF15 in skeletal muscle. Future studies should shed light on this issue.

3.2. Liver

Alterations in liver function are frequently observed in insulin resistance and type 2 diabetes mellitus. In fact, many patients suffering these metabolic alterations present nonalcoholic fatty liver disease (NAFLD), defined by a hepatic lipid accumulation >5% of the liver weight [60]. Hepatic lipid accumulation can also trigger inflammation, resulting in more severe liver disorders such as nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). Intriguingly, although hepatic lipid accumulation results from insulin resistance, it also contributes to hepatic insulin resistance [61], thereby suggesting that reversing hepatic steatosis can delay the progression from prediabetes to overt type 2 diabetes mellitus. Unregulated lipogenesis and reduced FA oxidation contribute to lipid accumulation in the liver, with AMPK regulating both processes in hepatocytes. Thus, as mentioned above, AMPK-mediated ACC inhibition leads to a decrease in intracellular levels of malonyl-CoA, which is both a precursor for FA biosynthesis and a potent allosteric inhibitor of FA oxidation. Moreover, AMPK reduces the expression of lipogenic genes by phosphorylating transcription factors such as sterol regulatory element binding protein-1c (SREBP-1c) [62] and carbohydrate-responsive element-binding protein (ChREBP) [63]. It has been reported that HFDs reduce hepatic phospho-AMPK levels and increase phospho-ERK levels, with GW501516 treatment preventing these changes by a mechanism that may involve an increased AMP/ATP ratio and elevated plasma β -hydroxybutyrate levels, indicating enhanced hepatic FA oxidation [64] (Figure 2). Interestingly, a different study reported that GW501516 treatment stimulated AMPK and ACC phosphorylation and attenuated FA synthesis in wild-type hepatocytes, but not in AMPK $\beta^{-/-}$ hepatocytes [65], thereby confirming the involvement of AMPK in these effects.

Autophagy is a catabolic process that delivers intracellular proteins and organelles to the lysosome during starvation for degradation and recycling, thereby promoting the redistribution of nutrients to maintain cellular energetic balance [66]. Notably, the inhibition of autophagy results in triglyceride accumulation and reduced FA oxidation in the liver, while drugs increasing autophagy alleviate liver steatosis in mice fed an HFD [67]. AMPK activation promotes autophagy through two different mechanisms: inhibition of the mammalian target of rapamycin (mTOR) protein kinase complex and direct phosphorylation of Unc-51-like kinase 1 (ULK1) [68]. Recently, it has been demonstrated that PPAR β/δ reduces hepatic steatosis and stimulates FA oxidation in the liver and hepatic cells by an autophagy-lysosomal pathway involving the AMPK-mTOR pathway [69] (Figure 2). More generally, the roles of PPARs and their novel ligands as potential drugs for the treatment of NAFLD have been reviewed recently [70].

Insulin resistance and type 2 diabetes mellitus are closely associated with a chronic low-grade inflammation characterized by an abnormal production of cytokines. Of these cytokines, interleukin 6 (IL-6) has been reported to induce hepatic insulin resistance [71]. IL-6 induces insulin resistance in the liver through the activation of signal transducer and activator of transcription 3 (STAT3) and the subsequent induction of suppressor of cytokine signaling 3 (SOCS3), which inhibits insulin signaling by interfering with insulin receptor activation, blocking IRS activation, and inducing IRS degradation [72]. In liver cells, PPAR β/δ activation was demonstrated to prevent IL-6-induced STAT3 activation

and SOCS3 upregulation by counteracting the reduction in phospho-AMPK levels, which inhibits STAT3 phosphorylation [73] (Figure 2). Consistent with this, the livers of *Ppard*^{-/-} mice show increased phospho-STAT3 levels. This action of PPAR β/δ prevents the reduction in IRS-1 and IRS-2 levels caused by exposure of hepatic cells to IL-6 [73].

3.3. Heart

The risk of developing heart failure is higher in patients with insulin resistance and type 2 diabetes mellitus, with inflammation being a key systemic factor contributing to this relationship [74]. Indeed, the progression of cardiac hypertrophy and heart failure usually entails a local rise in proinflammatory factors, which are under the transcriptional control of nuclear factor- κ B (NF- κ B). Notably, AMPK activation may block NF- κ B signaling through suppressing I κ B kinase activity [75]. It has been reported that PPAR β/δ activation reduces the lipid-induced expression of NF- κ B-target genes in the hearts of mice and in human cardiac cells, with these effects involving an AMPK-dependent mechanism [76] (Figure 2). In addition, NF- κ B activity has been reported to be increased in the hearts of PPAR β/δ -knockout mice compared with wild-type mice, which is consistent with the anti-inflammatory effects of PPAR β/δ activity.

ER stress contributes to the pathogenesis of diabetic cardiomyopathy by promoting apoptotic cell death in the myocardium [77]. PPAR β/δ activation prevents lipid-induced ER stress in the heart by inducing autophagy [78]. In addition, PPAR β/δ -knockout mice display a reduction in autophagic markers. However, in contrast to what has been reported for the liver [69], these effects of PPAR β/δ occur in an AMPK-independent manner.

4. Going the Other Way: The AMPK-PPAR β/δ Pathway

While previous sections of this review clearly demonstrate that many of the antidiabetic effects of PPAR β/δ agonists are mediated via AMPK activation, a few studies have reported the opposite, i.e., the regulation of PPAR β/δ by AMPK. In fact, a recent study proposed the existence of a positive loop between activated AMPK, PPAR β/δ , and myocyte enhancer factor 2A (MEF2A), the latter being a transcription factor that upregulates the expression of *Ppard* and *Glut4* [79]. The authors of this study demonstrated that AMPK activation increases PPAR β/δ levels via MEF2A [79]. As mentioned above, increased levels of PPAR β/δ would activate the NRF-1/CaMKK β pathway, thereby leading to AMPK activation, ultimately closing the loop (Figure 4). Thus, PPAR β/δ activates AMPK and AMPK activity influences PPAR β/δ levels, establishing a mutual cooperation that regulates MEF2A promoter activity and *Glut4* expression.

More recently, it has been reported that AMPK regulates PPAR β/δ phosphorylation, modulating its activity [80]. The authors of this study observed that the AMPK agonist metformin induced the phosphorylation of PPAR β/δ at Ser⁵⁰ through the common LXRXSXXXL phosphorylation motif recognized by this kinase, which localizes in the short N-terminal A/B activation domain of this nuclear receptor. Of note, AMPK-mediated phosphorylation of PPAR β/δ at Ser⁵⁰ resulted in an accumulation of the protein levels of this PPAR isotype, suggesting that its phosphorylation attenuated PPAR β/δ degradation. In fact, PPAR β/δ phosphorylation at Ser⁵⁰ inhibits the p62-mediated misfolded PPAR β/δ autophagic degradation. Despite the increase in PPAR β/δ levels caused by AMPK activation, the findings of this study suggest that PPAR β/δ phosphorylation inhibits transcriptional activity as a PPAR β/δ -Ser⁵⁰ mutant showed increased activity compared with wild-type PPAR β/δ . Although this study was conducted in cancer cell lines, the AMPK-mediated phosphorylation of PPAR β/δ attenuated glucose uptake by reducing the expression of *Glut1*, thereby suggesting that this pathway can have metabolic implications. Further studies are needed to confirm whether this pathway operates in metabolic tissues such as the liver and skeletal muscle and how it regulates metabolism.




Figure 4. Potential positive loop between activated AMPK, PPAR β/δ , and MEF2A. AMPK, AMP-activated protein kinase; CaMKK β , Ca²⁺/calmodulin-dependent protein kinase kinase- β ; MEF2A, myocyte enhancer factor 2A; NRF-1: nuclear respiratory factor 1; PPAR β/δ , peroxisome proliferator-activated receptor β/δ .

5. Conclusions and Perspectives

The development of novel drugs to treat type 2 diabetes mellitus continues to attract attention in the metabolism field. The PPAR β/δ -AMPK pathway is in the spotlight as it pharmacologically promotes the effects of exercise in skeletal muscle, such as increased glucose uptake and FA oxidation. This pathway also prevents lipid-induced ER stress and inflammation, thereby ameliorating insulin resistance. New specific molecular mechanisms indicating how this pathway ameliorates insulin resistance are beginning to emerge, such as the recently reported upregulation of GDF15 by PPAR β/δ agonists via AMPK. GDF15 upregulation activates AMPK, thereby implying that this mechanism contributes to the effects of PPAR β/δ agonists by sustaining AMPK activation. In addition, *Gdf15*^{-/-} mice show reduced AMPK activation in skeletal muscle, whereas GDF15 administration results in AMPK activation in this organ. Interestingly, this effect of GDF15 in AMPK activation seems to be independent of the central receptor GFRAL, thereby suggesting that this cytokine exerts autocrine/paracrine effects through yet to be determined receptors. Future studies aimed at expanding the mechanisms of action of the PPAR β/δ -AMPK pathway may facilitate the development of new antidiabetic compounds with improved efficacy and minimal side effects for the treatment of insulin resistance and the prevention of its progression to type 2 diabetes mellitus. In fact, type 2 diabetic patients might benefit from the development of new antidiabetic drugs targeting both PPAR β/δ and AMPK given the positive feedback loop that potentiates them each other. This might result in a new generation of molecules for the prevention and treatment of obesity-induced insulin resistance and type 2 diabetes mellitus. It is noteworthy that PPAR β/δ , similar to PPAR α and PPAR γ , has been ascribed pro- and anti-tumor activities that have to be considered in the development of new candidate drugs [5,81,82]. Several factors can contribute to the highly debated functional role of PPAR β/δ in tumorigenesis or carcinogenesis. For instance, the tumor promoter effects of PPAR β/δ agonists have been mostly observed in animal models. Although these animal models are a valuable tool for basic tumor research, they show some limitations and the conclusions obtained from these studies are not always confirmed in human beings. Thus, the expression of the different PPAR isotypes is higher in rodent than in human cells and the regulation of these nuclear receptors is also different depending on the cell type studied [5]. These differences may explain why, after decades of treating patients with the PPAR α activators fibrates, no incidence of carcinogenesis has

been reported, whereas it is well-known that administration of these drugs to rodents leads to carcinogenesis. Either way, as controversy about the role of PPAR β/δ agonists in cancer still remains, to minimize side effects, the success of PPAR β/δ -based treatment of insulin resistance would benefit from the development of innovative strategies for organ- or cell-type-specific drug delivery or release systems.

Funding: This work was funded by the Ministerio de Economía y Competitividad of the Spanish Government (RTI2018-093999-B-100) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM). CIBERDEM is an initiative of the Instituto de Salud Carlos III (IS-CIII)—Ministerio de Economía y Competitividad.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Language Services of the University of Barcelona for revising the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Zimmet, P.; Alberti, K.G.M.M.; Shaw, J. Global and societal implications of the diabetes epidemic. *Nature* **2001**, *414*, 782–787. [[CrossRef](#)]
2. Alejandro, E.U.; Gregg, B.; Blandino-Rosano, M.; Cras-Méneur, C.; Bernal-Mizrachi, E. Natural history of β -cell adaptation and failure in type 2 diabetes. *Mol. Asp. Med.* **2015**, *42*, 19–41. [[CrossRef](#)]
3. Tripathy, D.; Chavez, A.O. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. *Curr. Diab. Rep.* **2010**, *10*, 184–191. [[CrossRef](#)] [[PubMed](#)]
4. Giordano Attianese, G.M.P.; Desvergne, B. Integrative and systemic approaches for evaluating PPAR β/δ (PPARD) function. *Nucl. Recept. Signal* **2015**, *13*, 13001. [[CrossRef](#)] [[PubMed](#)]
5. Tan, N.S.; Vázquez-Carrera, M.; Montagner, A.; Sng, M.K.; Guillou, H.; Wahli, W. Transcriptional control of physiological and pathological processes by the nuclear receptor PPAR β/δ . *Prog. Lipid Res.* **2016**, *64*, 98–122. [[CrossRef](#)]
6. Vázquez-Carrera, M. Unraveling the Effects of PPAR β/δ on Insulin Resistance and Cardiovascular Disease. *Trends Endocrinol. Metab.* **2016**, *27*, 319–334. [[CrossRef](#)] [[PubMed](#)]
7. Unsworth, A.J.; Flora, G.D.; Gibbins, J.M. Non-genomic effects of nuclear receptors: Insights from the anucleate platelet. *Cardiovasc. Res.* **2018**, *114*, 645–655. [[CrossRef](#)]
8. Yoo, T.; Ham, S.A.; Lee, W.J.; Hwang, S.I.; Park, J.A.; Hwang, J.S.; Hur, J.; Shin, H.C.; Han, S.G.; Lee, C.H.; et al. Ligand-Dependent Interaction of PPAR δ With T-Cell Protein Tyrosine Phosphatase 45 Enhances Insulin Signaling. *Diabetes* **2018**, *67*, 360–371. [[CrossRef](#)] [[PubMed](#)]
9. Lin, S.-C.; Hardie, D.G. AMPK: Sensing Glucose as well as Cellular Energy Status. *Cell Metab.* **2018**, *27*, 299–313. [[CrossRef](#)] [[PubMed](#)]
10. Hardie, D.G.; Schaffer, B.E.; Brunet, A. AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. *Trends Cell Biol.* **2016**, *26*, 190–201. [[CrossRef](#)]
11. Day, E.A.; Ford, R.J.; Steinberg, G.R. AMPK as a Therapeutic Target for Treating Metabolic Diseases. *Trends Endocrinol. Metab.* **2017**, *28*, 545–560. [[CrossRef](#)]
12. He, L.; Wondisford, F.E. Metformin action: Concentrations matter. *Cell Metab.* **2015**, *21*, 159–162. [[CrossRef](#)]
13. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* **2006**, *444*, 337–342. [[CrossRef](#)] [[PubMed](#)]
14. Lee, Y.S.; Kim, W.S.; Kim, K.H.; Yoon, M.J.; Cho, H.J.; Shen, Y.; Ye, J.-M.; Lee, C.H.; Oh, W.K.; Kim, C.T.; et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes* **2006**, *55*, 2256–2264. [[CrossRef](#)]
15. Corton, J.M.; Gillespie, J.G.; Hawley, S.A.; Hardie, D.G. 5-Aminoimidazole-4-carboxamide ribonucleoside: A specific method for activating AMP-activated protein kinase in intact cells? *Eur. J. Biochem.* **1995**, *229*, 558–565. [[CrossRef](#)] [[PubMed](#)]
16. Goransson, O.; McBride, A.; Hawley, S.A.; Ross, F.A.; Shpiro, N.; Foretz, M.; Viollet, B.; Hardie, D.G.; Sakamoto, K. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. *J. Biol. Chem.* **2007**, *282*, 32549–32560. [[CrossRef](#)] [[PubMed](#)]
17. Sanders, M.J.; Ali, Z.S.; Hegarty, B.D.; Heath, R.; Snowden, M.A.; Carling, D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. *J. Biol. Chem.* **2007**, *282*, 32539–32548. [[CrossRef](#)]

18. Racanelli, A.C.; Rothbart, S.B.; Heyer, C.L.; Moran, R.G. Therapeutics by cytotoxic metabolite accumulation: Pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. *Cancer Res.* **2009**, *69*, 5467–5474. [[CrossRef](#)]
19. Pirkmajer, S.; Kulkarni, S.S.; Tom, R.Z.; Ross, F.A.; Hawley, S.A.; Hardie, D.G.; Zierath, J.R.; Chibalin, A.V. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation. *Diabetes* **2015**, *64*, 360–369. [[CrossRef](#)]
20. Dasgupta, B.; Seibel, W. Compound C/Dorsomorphin: Its Use and Misuse as an AMPK Inhibitor. *Methods Mol. Biol.* **2018**, *1732*, 195–202.
21. Dite, T.A.; Langendorf, C.G.; Hoque, A.; Galic, S.; Rebello, R.J.; Ovens, A.J.; Lindqvist, L.M.; Ngoei, K.R.W.; Ling, N.X.Y.; Furicet, L.; et al. AMP-activated protein kinase selectively inhibited by the type II inhibitor SBI-0206965. *J. Biol. Chem.* **2018**, *293*, 8874–8885. [[CrossRef](#)] [[PubMed](#)]
22. Hardie, D.G.; Ross, F.A.; Hawley, S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 251–262. [[CrossRef](#)] [[PubMed](#)]
23. Ruderman, N.B.; Carling, D.; Prentki, M.; Cacicedo, J.M. AMPK, insulin resistance, and the metabolic syndrome. *J. Clin. Investig.* **2013**, *123*, 2764–2772. [[CrossRef](#)]
24. DeFronzo, R.A.; Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. *Diabetes Care* **2009**, *32* (Suppl. 2), S157–S163. [[CrossRef](#)]
25. DeFronzo, R.A.; Ferrannini, E.; Sato, Y.; Felig, P.; Wahren, J. Synergistic interaction between exercise and insulin on peripheral glucose uptake. *J. Clin. Investig.* **1981**, *68*, 1468–1474. [[CrossRef](#)] [[PubMed](#)]
26. Gustafson, B.; Hedjazifar, S.; Gogg, S.; Hammarstedt, A.; Smith, U. Insulin resistance and impaired adipogenesis. *Trends Endocrinol. Metab.* **2015**, *26*, 193–200. [[CrossRef](#)]
27. Chen, Q.; Xie, B.; Zhu, S.; Rong, P.; Sheng, Y.; Ducommun, S.; Chen, L.; Quan, C.; Li, M.; Sakamoto, K.; et al. A Tbc1d1 Ser231Ala-knockin mutation partially impairs AICAR- but not exercise-induced muscle glucose uptake in mice. *Diabetologia* **2017**, *60*, 336–345. [[CrossRef](#)]
28. Liu, Y.; Lai, Y.C.; Hill, E.V.; Tyteca, T.; Carpentier, S.; Ingvaldsen, A.; Vertommen, D.; Lantier, L.; Foretz, M.; Dequiedt, F.; et al. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is an AMPK target participating in contraction-stimulated glucose uptake in skeletal muscle. *Biochem. J.* **2013**, *455*, 195–206. [[CrossRef](#)]
29. Jaiswal, N.; Gavin, M.G.; Quinn, W.J., 3rd; Luongo, T.S.; Gelfer, R.G.; Baur, J.A.; Titchenell, P.M. The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis. *Mol. Metab.* **2019**, *28*, 1–13. [[CrossRef](#)] [[PubMed](#)]
30. Krämer, D.K.; Al-Khalili, L.; Perrini, S.; Skogsberg, J.; Wretenberg, P.; Kannisto, K.; Wallberg-Henriksson, H.; Ehrenborg, E.; Zierath, J.R.; Krook, A. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. *Diabetes* **2005**, *54*, 1157–1163. [[CrossRef](#)]
31. Krämer, D.K.; Al-Khalili, L.; Guigas, B.; Leng, Y.; Garcia-Roves, P.M.; Krook, A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. *J. Biol. Chem.* **2007**, *282*, 19313–19320. [[CrossRef](#)]
32. Wang, Y.X.; Zhang, C.L.; Yu, R.T.; Cho, H.K.; Nelson, M.C.; Bayuga-Ocampo, C.R.; Ham, J.; Kang, H.; Evans, R.M. Regulation of muscle fiber type and running endurance by PPARdelta. *PLoS Biol.* **2004**, *2*, e294. [[CrossRef](#)]
33. Narkar, V.A.; Downes, M.; Yu, R.T.; Emblar, E.; Wang, Y.X.; Banayo, E.; Mihaylova, M.M.; Nelson, M.C.; Zou, Y.; Juguilon, H.; et al. AMPK and PPARdelta agonists are exercise mimetics. *Cell* **2008**, *134*, 405–415. [[CrossRef](#)]
34. Gan, Z.; Burkart-Hartman, E.M.; Han, D.-H.; Finck, B.; Leone, T.C.; Smith, E.Y.; Ayala, J.E.; Holloszy, J.; Kelly, D.P. The nuclear receptor PPAR β / δ programs muscle glucose metabolism in cooperation with AMPK and MEF2. *Genes Dev.* **2011**, *25*, 2619–2630. [[CrossRef](#)] [[PubMed](#)]
35. Australian Government Department of Health, Therapeutic Goods Administration. Available online: <https://www.tga.gov.au/book-page/12-cardarine#fn8> (accessed on 2 July 2021).
36. The World Anti-Doping Agency. The World Anti-Doping Code: The 2009 Prohibited List International Standard. 2009, p. 6. Available online: https://www.wada-ama.org/sites/default/files/resources/files/WADA_Prohibited_List_2009_EN.pdf (accessed on 5 July 2021).
37. Schuler, M.; Ali, F.; Chambon, C.; Duteil, D.; Bornert, J.-M.; Tardivel, A.; Desvergne, B.; Wahli, W.; Chambon, P.; Metzger, D. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. *Cell Metab.* **2006**, *4*, 407–414. [[CrossRef](#)] [[PubMed](#)]
38. Hancock, C.R.; Han, D.H.; Chen, M.; Terada, S.; Yasuda, T.; Wright, D.C.; Holloszy, J.O. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 7815–7820. [[CrossRef](#)]
39. Koh, J.H.; Hancock, C.R.; Terada, S.; Higashida, K.; Holloszy, J.O.; Han, D.H. PPAR β Is Essential for Maintaining Normal Levels of PGC-1 α and Mitochondria and for the Increase in Muscle Mitochondria Induced by Exercise. *Cell Metab.* **2017**, *25*, 1176–1185. [[CrossRef](#)]
40. Coll, T.; Alvarez-Guardia, D.; Barroso, E.; Gómez-Foix, A.M.; Palomer, X.; Laguna, J.C.; Vázquez-Carrera, M. Activation of peroxisome proliferator-activated receptor- δ by GW501516 prevents fatty acid-induced nuclear factor-kB activation and insulin resistance in skeletal muscle cells. *Endocrinology* **2010**, *151*, 1560–1569. [[CrossRef](#)]
41. Petersen, M.C.; Shulman, G.I. Mechanisms of Insulin Action and Insulin Resistance. *Physiol Rev.* **2018**, *98*, 2133–2223. [[CrossRef](#)] [[PubMed](#)]
42. Salvadó, L.; Palomer, X.; Barroso, E.; Vázquez-Carrera, M. Targeting endoplasmic reticulum stress in insulin resistance. *Trends Endocrinol. Metab.* **2015**, *26*, 438–448. [[CrossRef](#)] [[PubMed](#)]

43. Terai, K.; Hiramoto, Y.; Masaki, M.; Sugiyama, S.; Kuroda, T.; Hori, M.; Kawase, I.; Hirota, H. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. *Mol. Cell. Biol.* **2005**, *25*, 9554–9575. [[CrossRef](#)] [[PubMed](#)]
44. Dong, Y.; Zhang, M.; Wang, S.; Liang, B.; Zhao, Z.; Liu, C.; Wu, M.; Choi, H.C.; Lyons, T.J.; Zou, M.H. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. *Diabetes* **2010**, *59*, 1386–1396. [[CrossRef](#)] [[PubMed](#)]
45. Dong, Y.; Zhang, M.; Liang, B.; Xie, Z.; Zhao, Z.; Asfa, S.; Choi, H.C.; Zou, M.-H. Reduction of AMP-activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. *Circulation* **2010**, *121*, 792–803. [[CrossRef](#)]
46. Wang, Y.; Wu, Z.; Li, D.; Wang, D.; Wang, X.; Feng, X.; Xia, M. Involvement of oxygen-regulated protein 150 in AMP-activated protein kinase-mediated alleviation of lipid-induced endoplasmic reticulum stress. *J. Biol. Chem.* **2011**, *286*, 11119–11131. [[CrossRef](#)]
47. Du, J.; Guan, T.; Zhang, H.; Xia, Y.; Liu, F.; Zhang, Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. *Biochem. Biophys. Res. Commun.* **2008**, *368*, 402–407. [[CrossRef](#)]
48. Hwang, S.L.; Jeong, Y.T.; Li, X.; Kim, Y.D.; Lu, Y.; Chang, Y.-C.; Lee, I.-K.; Chang, H.W. Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress induced insulin resistance in skeletal muscle. *Br. J. Pharmacol.* **2013**, *169*, 69–81. [[CrossRef](#)] [[PubMed](#)]
49. Aguilar-Recarte, D.; Barroso, E.; Gumà, A.; Pizarro-Delgado, J.; Peña, L.; Ruat, M.; Palomer, X.; Wahli, W.; Vázquez-Carrera, M. GDF15 mediates the metabolic effects of PPARbeta/delta by activating AMPK. *Cell Rep.* **2021**, in press.
50. Hsiao, E.C.; Koniaris, L.G.; Zimmers-Koniaris, T.; Sebald, S.M.; Huynh, T.V.; Lee, S.J. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. *Mol. Cell. Biol.* **2000**, *20*, 3742–3751. [[CrossRef](#)]
51. Tsai, V.W.W.; Husaini, Y.; Sainsbury, A.; Brown, D.A.; Breit, S.N. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases. *Cell Metab.* **2018**, *28*, 353–368. [[CrossRef](#)]
52. Baek, S.J.; Eling, T. Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases. *Pharmacol. Ther.* **2019**, *198*, 46–58. [[CrossRef](#)]
53. Klein, A.B.; Nicolaisen, T.S.; Ørtenblad, N.; Gejl, K.D.; Jensen, R.; Fritzen, A.M.; Larsen, E.L.; Karstoft, K.; Poulsen, H.E.; Morville, T.; et al. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise. *Nat. Commun.* **2021**, *12*, 1041. [[CrossRef](#)]
54. Emmerson, P.J.; Wang, F.; Du, Y.; Liu, Q.; Pickard, R.T.; Gonciarz, M.D.; Coskun, T.; Hamang, M.J.; Sindelar, D.K.; Ballmanet, K.K.; et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. *Nat. Med.* **2017**, *23*, 1215–1219. [[CrossRef](#)] [[PubMed](#)]
55. Yang, L.; Chang, C.-C.; Sun, Z.; Madsen, D.; Zhu, H.; Padkjær, S.B.; Wu, X.; Huang, T.; Hultman, K.; Paulsen, S.J.; et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. *Nat. Med.* **2017**, *23*, 1158–1166. [[CrossRef](#)]
56. Mullican, S.E.; Lin-Schmidt, X.; Chin, C.-N.; Chavez, J.A.; Furman, J.L.; Armstrong, A.A.; Beck, S.C.; South, V.J.; Dinh, T.Q.; Cash-Mason, T.D.; et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. *Nat. Med.* **2017**, *23*, 1150–1157. [[CrossRef](#)] [[PubMed](#)]
57. Hsu, J.Y.; Crawley, S.; Chen, M.; Ayupova, D.A.; Lindhout, D.A.; Higbee, J.; Kutach, A.; Joo, W.; Gao, Z.; Fu, D.; et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. *Nature* **2017**, *550*, 255–259. [[CrossRef](#)] [[PubMed](#)]
58. Chung, H.K.; Ryu, D.; Kim, K.S.; Chang, J.Y.; Kim, Y.K.; Yi, H.-S.; Kang, S.G.; Choi, M.J.; Lee, S.E.; Jung, S.-B.; et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. *J. Cell Biol.* **2017**, *216*, 149–165. [[CrossRef](#)]
59. Laurens, C.; Parmar, A.; Murphy, E.; Carper, D.; Lair, B.; Maes, P.; Vion, J.; Boulet, N.; Fontaine, C.; Marquès, M.; et al. Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans. *JCI Insight* **2020**, *5*, e131870. [[CrossRef](#)]
60. Rinella, M.E. Nonalcoholic fatty liver disease: A systematic review. *JAMA* **2015**, *313*, 2263–2273. [[CrossRef](#)]
61. Smith, B.K.; Marcinko, K.; Desjardins, E.M.; Lally, J.S.; Ford, R.J.; Steinberg, G.R. Treatment of nonalcoholic fatty liver disease: Role of AMPK. *Am. J. Physiol. Endocrinol. Metab.* **2016**, *311*, E730–E740. [[CrossRef](#)]
62. Li, Y.; Xu, S.; Mihaylova, M.M.; Zheng, B.; Hou, X.; Jiang, B.; Park, O.; Luo, Z.; Lefai, E.; Shyy, J.Y.; et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. *Cell Metab.* **2011**, *13*, 376–388. [[CrossRef](#)] [[PubMed](#)]
63. Kawaguchi, T.; Osatomi, K.; Yamashita, H.; Kabashima, T.; Uyeda, K. Mechanism for fatty acid “sparing” effect on glucose-induced transcription: Regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. *J. Biol. Chem.* **2002**, *277*, 3829–3835. [[CrossRef](#)] [[PubMed](#)]
64. Barroso, E.; Rodriguez-Calvo, R.; Serrano-Marco, L.; Astudillo, A.M.; Balsinde, J.; Palomer, X.; Vázquez-Carrera, M. The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. *Endocrinology* **2011**, *152*, 1848–1859. [[CrossRef](#)] [[PubMed](#)]

65. Bojic, L.A.; Telford, D.E.; Fullerton, M.D.; Ford, R.J.; Sutherland, B.G.; Edwards, J.Y.; Sawyez, C.G.; Gros, R.; Kemp, B.E.; Steinberg, G.R.; et al. PPAR δ activation attenuates hepatic steatosis in Ldlr $^{-/-}$ mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. *J. Lipid Res.* **2014**, *55*, 1254–1266. [[CrossRef](#)] [[PubMed](#)]
66. Yorimitsu, T.; Klionsky, D.J. Autophagy: Molecular machinery for self-eating. *Cell Death Differ.* **2005**, *12* (Suppl. 2), 1542–1552. [[CrossRef](#)]
67. Singh, R.; Kaushik, S.; Wang, Y.; Xiang, Y.; Novak, I.; Komatsu, M.; Tanaka, K.; Cuervo, A.M.; Czaja, M.J. Autophagy regulates lipid metabolism. *Nature* **2009**, *458*, 1131–1135. [[CrossRef](#)]
68. Kim, J.; Kundu, M.; Viollet, B.; Guan, K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* **2011**, *13*, 132–141. [[CrossRef](#)]
69. Tong, L.; Wang, L.; Yao, S.; Jin, L.; Yang, J.; Zhang, Y.; Ning, G.; Zhang, Z. PPAR δ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation. *Cell Death Dis.* **2019**, *10*, 197. [[CrossRef](#)]
70. Fougerat, A.; Montagner, A.; Loiseau, N.; Guillou, H.; Wahli, W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. *Cells* **2020**, *9*, 1638. [[CrossRef](#)]
71. Yamaguchi, K.; Nishimura, T.; Ishiba, H.; Seko, Y.; Okajima, A.; Fujii, H.; Tochiki, N.; Umemura, A.; Moriguchi, M.; Sumida, Y.; et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice. *Liver Int.* **2015**, *35*, 550–561. [[CrossRef](#)] [[PubMed](#)]
72. Galic, S.; Sachithanandan, N.; Kay, T.W.; Steinberg, G.R. Suppressor of cytokine signalling (SOCS) proteins as guardians of inflammatory responses critical for regulating insulin sensitivity. *Biochem. J.* **2014**, *461*, 177–188. [[CrossRef](#)]
73. Serrano-Marco, L.; Barroso, E.; Kochairi, I.E.; Palomer, X.; Michalik, L.; Wahli, W.; Vázquez-Carrera, M. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. *Diabetologia* **2012**, *55*, 743–751. [[CrossRef](#)] [[PubMed](#)]
74. Maack, C.; Lehrke, M.; Backs, J.; Heinzl, F.R.; Hulot, J.-S.; Marx, N.; Paulus, W.J.; Rossignol, P.; Taegtmeyer, H.; Bauersachs, J.; et al. Heart failure and diabetes: Metabolic alterations and therapeutic interventions: A state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. *Eur. Heart J.* **2018**, *39*, 4243–4254. [[CrossRef](#)] [[PubMed](#)]
75. Li, H.L.; Yin, R.; Chen, D.; Liu, D.; Wang, D.; Yang, Q.; Dong, Y.G. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. *J. Cell. Biochem.* **2007**, *100*, 1086–1099. [[CrossRef](#)] [[PubMed](#)]
76. Alvarez-Guardia, D.; Palomer, X.; Coll, T.; Serrano, L.; Rodríguez-Calvo, R.; Davidson, M.M.; Merlos, M.; Kochairi, I.E.; Michalik, L.; Wahli, W.; et al. PPAR β/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. *Biochim. Biophys. Acta* **2011**, *1811*, 59–67. [[CrossRef](#)]
77. Palomer, X.; Pizarro-Delgado, J.; Vázquez-Carrera, M. Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets? *Trends Pharmacol. Sci.* **2018**, *39*, 452–467. [[CrossRef](#)] [[PubMed](#)]
78. Palomer, X.; Capdevila-Busquets, E.; Botteri, G.; Salvadó, L.; Barroso, E.; Davidson, M.M.; Michalik, L.; Wahli, W.; Vázquez-Carrera, M. PPAR β/δ attenuates palmitate-induced endoplasmic reticulum stress and induces autophagic markers in human cardiac cells. *Int. J. Cardiol.* **2014**, *174*, 110–118. [[CrossRef](#)]
79. Koh, J.H.; Hancock, C.R.; Han, D.H.; Holloszy, J.O.; Nair, K.S.; Dasari, S. AMPK and PPAR β positive feedback loop regulates endurance exercise training-mediated GLUT4 expression in skeletal muscle. *Am. J. Physiol. Endocrinol. Metab.* **2019**, *316*, E931–E939. [[CrossRef](#)]
80. Ding, J.; Gou, Q.; Jia, X.; Liu, Q.; Jin, J.; Shi, J.; Hou, Y. AMPK phosphorylates PPAR δ to mediate its stabilization, promote glucose and glutamine uptake, and inhibit colon tumor growth. *J. Biol. Chem.* **2021**, 100954. [[CrossRef](#)]
81. Wagner, N.; Wagner, K.-D. PPARs and Angiogenesis-Implications in Pathology. *Int. J. Mol. Sci.* **2020**, *21*, 5723. [[CrossRef](#)]
82. Cheng, H.S.; Yip, Y.S.; Lim, E.K.Y.; Wahli, W.; Tan, N.S. PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis. *Cancers* **2021**, *13*, 2153. [[CrossRef](#)]